Bispecific antibody substituting for functional proteins

Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C424S133100, C424S145100, C424S146100, C424S094640, C514S013500, C514S013700, C514S014100, C514S014400

Reexamination Certificate

active

08062635

ABSTRACT:
The present inventors succeeded in constructing bispecific antibodies, which bind to both the blood coagulation factor IX/activated blood coagulation factor IX and blood coagulation factor X, and functionally substitute for blood coagulation factor VIII/activated blood coagulation factor VIII which enhances the enzymatic reaction.

REFERENCES:
patent: 4208479 (1980-06-01), Zuk et al.
patent: 4444878 (1984-04-01), Paulus
patent: 4474893 (1984-10-01), Reading
patent: 5496549 (1996-03-01), Yamazaki et al.
patent: 5591828 (1997-01-01), Bosslet et al.
patent: 5744446 (1998-04-01), Lollar et al.
patent: 5945311 (1999-08-01), Lindhofer et al.
patent: 6005091 (1999-12-01), Blackburn et al.
patent: 6010902 (2000-01-01), Ledbetter et al.
patent: 7033590 (2006-04-01), Scheiflinger et al.
patent: 2002/0009430 (2002-01-01), Lindhofer et al.
patent: 2002/0062010 (2002-05-01), Arathoon et al.
patent: 2002/0142374 (2002-10-01), Gallo et al.
patent: 2003/0207346 (2003-11-01), Arathoon et al.
patent: 2005/0130224 (2005-06-01), Saito et al.
patent: 2005/0164307 (2005-07-01), Kojima et al.
patent: 2005/0196397 (2005-09-01), Scheiflinger et al.
patent: 2005/0244416 (2005-11-01), Jung
patent: 2006/0159673 (2006-07-01), Kojima
patent: 2007/0087381 (2007-04-01), Kojima
patent: 2008/0075712 (2008-03-01), Hattori et al.
patent: 2009/0117097 (2009-05-01), Igawa et al.
patent: 2009/0263392 (2009-10-01), Igawa et al.
patent: 2009/0324589 (2009-12-01), Igawa et al.
patent: 2010/0003254 (2010-01-01), Hattori et al.
patent: 2010/0015133 (2010-01-01), Igawa et al.
patent: 2010/0055092 (2010-03-01), Hasegawa et al.
patent: 2011/0076275 (2011-03-01), Igawa et al.
patent: 2011/0111406 (2011-05-01), Igawa et al.
patent: 2009290162 (2010-04-01), None
patent: 2 019 559 (1990-12-01), None
patent: 2 603 264 (2006-10-01), None
patent: 0 369 566 (1990-05-01), None
patent: 0 404 097 (1990-12-01), None
patent: 1 505 148 (2005-02-01), None
patent: 1510943 (2005-03-01), None
patent: 0 979 281 (2005-07-01), None
patent: 1 688 488 (2006-08-01), None
patent: 1 693 448 (2006-08-01), None
patent: 1 220 923 (2007-06-01), None
patent: 1870459 (2007-12-01), None
patent: 1 876 236 (2008-01-01), None
patent: 2 275 443 (2011-01-01), None
patent: 2-145187 (1990-06-01), None
patent: 5-501543 (1993-03-01), None
patent: 5-184383 (1993-07-01), None
patent: 5-199894 (1993-08-01), None
patent: 5-203652 (1993-08-01), None
patent: 5-213775 (1993-08-01), None
patent: 5-304992 (1993-11-01), None
patent: 09506001 (1997-06-01), None
patent: 10-165184 (1998-06-01), None
patent: 10-511085 (1998-10-01), None
patent: 11-71288 (1999-03-01), None
patent: 11-506310 (1999-06-01), None
patent: 2001-523971 (2001-11-01), None
patent: 2002-518041 (2002-06-01), None
patent: 2003-055398 (2003-02-01), None
patent: 2003-509049 (2003-03-01), None
patent: WO 91/08770 (1991-06-01), None
patent: WO 93/11161 (1993-06-01), None
patent: 9533844 (1995-12-01), None
patent: 9601653 (1996-01-01), None
patent: WO 96/16673 (1996-06-01), None
patent: 9627011 (1996-09-01), None
patent: WO 96/26964 (1996-09-01), None
patent: 9803546 (1998-01-01), None
patent: WO 98/50431 (1998-11-01), None
patent: WO 99/10494 (1999-03-01), None
patent: WO 99/67359 (1999-12-01), None
patent: WO 01/19992 (2001-03-01), None
patent: WO 03/091424 (2003-01-01), None
patent: WO 03/035835 (2003-05-01), None
patent: WO 03/042231 (2003-05-01), None
patent: WO 03/087163 (2003-10-01), None
patent: WO 2004/065611 (2004-08-01), None
patent: WO 2005/035754 (2005-04-01), None
patent: WO 2005/035756 (2005-04-01), None
patent: 2006106905 (2006-10-01), None
patent: WO 2006/106903 (2006-10-01), None
patent: WO 2006/109592 (2006-10-01), None
patent: WO 2007/114325 (2007-10-01), None
patent: WO 2007/142325 (2007-12-01), None
patent: WO 2009/041621 (2009-04-01), None
patent: WO 2009/041643 (2009-04-01), None
patent: WO 2009/125825 (2009-10-01), None
patent: WO 2009/139822 (2009-11-01), None
patent: WO 2010/035769 (2010-04-01), None
Bolton-Maggs et al. The Lancet, 2003, 1801-1809.
Hsia et al., Am. J. Hematol. 1008, 83:318-320.
Menegatti et al., Semin Thromb Hemost 2009 35:407-415.
Bajaj et al., J Biol Chem 1985, 260:11574-11580.
Bessos et al., Thrombosis Research, 1985, 40:863-867.
Nilsson et al., 1986, Proc. Natl Acad Sci USA, 83:9169-9173.
Price et al., Anaesthesia, 2004,59:483-492.
Rudikoff et al., Proc Natl Acad Sci U S A. Mar. 1982;79(6):1979-83.
Janeway et al., Immunobiology, 3rdedition, 1997, Garland Press, pp. 3:1 to 3:11.
William E. Paul, M.D. ed., Fundamental Immunology, 3d ed. 1993, p. 242.
Portolano et al., J Immunol., 1993, 150:880-887.
Asselta et al., Semin Thromb Hemost 2009 35:382-389.
Association of Hemophilia Clinic Directors of Canada, “Hemophilia and Von Willebrand's disease: 2. Management Association of Hemophilia Clinic Directors of Canada”, Canadian Medical Association Journal 153(2):147-157, 1995.
Davie et al., “The coagulation cascade: Initiation, maintenance, and regulation”, Biochemistry 30(43):10363-10370, 1991.
Grosse-Hovest et al., “A recombinant bispecific single-chain antibody induces targeted, supra-agonistic CD28-stimulation and tumor cell killing”, European Journal of Immunology 33(5):1334-1340, 2003.
Lenting et al., “The life cycle of coagulation factor VIII in view of its structure and function”, Blood 92(11):3983-3996, 1998.
Piper et al., “Interferon therapy in primary care”, Primary Care Update for Ob/Gyns 8(4):163-169, 2001.
Ruef et al., “A bispecific antifibrin-antiplatelet urokinase conjugate (BAAUC) induces enhanced clot lysis and inhibits platelet aggregation”, Thombosis and Haemostasis 82(1):109-114, 1999.
Shima et al., “Factor VIII Taitei Kotai (2), Ketsuyubyo A Kanja Katsueki ni okeru in vitro Gyoko Kassei no Kento”, Rinsho Ketsueki 46(8):777, 2005 (with English translation).
Soeda et al., “Factor VIII Taitei Kotai (1) Ko FIXa/FX bispecific Kotai no Sakusei oyobi characterization”, Rinsho Ketsueki, 46(8):728, 2005 (with English translation).
Soeda et al., “Phage library-ho ni yori Sakusei shita Ko-FIXa/Ko-FX bispecific Kotai no FVIII Taitei Sayo”, Japanese Journal of Thrombosis and Hemstasis, 16(5):526, 2005 (with English translation).
Bebbington et al., “High-Level Expression of a Recombinant Antibody from Myeloma Cells Using a Glutamine Synthetase Gene as an Amplifiable Selectable Marker,”Biotechnology(N Y), 10:169-175 (1992).
Bos et al., “Enhanced Transfection of a Bacterial Plasmid into Hybridoma Cells by Electroporation: Application for the Selection of Hybrid Hybridoma (Quadroma) Cell Lines,”Hybridoma, 11:41-51 (1992).
Brennan et al., “Preparation of Bispecific Antibodies by Chemical Recombination of Monoclonal Immunoglobulin G1 Fragments,”Science, 229:81-83 (1985).
Carter, “Bispecific human IgG by design,”J. Immunol. Methods, 248:7-15 (2001).
Deng et al., “An Agonist Murine Monoclonal Antibody to the Human c-Mpl Receptor Stimulates Megakaryocytopoiesis,”Blood, 92:1981-1988 (1998).
Francois et al., “Construction of a Bispecific Antibody Reacting with the α-and β-Chains of the Human IL-2 Receptor,”J. Immunol., 150:4610-4619 (1993).
GenPept Accession No. AAC26541, “anti BoNT/A Hc scFv antibody [synthetic construct],” 1 page (Aug. 1, 2001).
Hämmerling et al., “Use of Hybrid Antibody with Anti-γG and Anti-Ferritin Specificities in Locating Cell Surface Antigens by Electron Microscopy,”J. Exp. Med., 128:1461-1473 (1968).
Holliger et al., “‘Diabodies’: Small bivalent and bispecific antibody fragments,”Proc. Natl. Acad. Sci. USA, 90:6444-6448 (1993).
Huse et al., “Generation of a Large Combinatorial Library of the Immunoglobulin Repertoire in Phage Lambda,”Science, 246:1275-1281 (1989).
Kang et al., “Linkage of recognition and replication functions by assembling combinatorial antibody Fab libraries along phage surfaces,”Proc. Natl. Acad. Sci. USA, 88:4363-4366 (

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Bispecific antibody substituting for functional proteins does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Bispecific antibody substituting for functional proteins, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Bispecific antibody substituting for functional proteins will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-4261704

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.